US8147866 — Transmucosal delivery devices with enhanced uptake
Method of Use · Assigned to Biodelivery Sciences International Inc · Expires 2027-07-23 · 1y remaining
What this patent protects
This patent protects methods and devices for enhancing the absorption of certain medications, such as fentanyl or buprenorphine, through the mucous membranes.
USPTO Abstract
The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment.
Drugs covered by this patent
- Subutex (Buprenorphine Hydrochloride) · Indivior
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1769 |
— | Subutex |
U-1769 |
— | Subutex |
U-1769 |
— | Subutex |
U-1521 |
— | Subutex |
U-1521 |
— | Subutex |
U-1521 |
— | Subutex |
U-1769 |
— | Subutex |
U-1769 |
— | Subutex |
U-1769 |
— | Subutex |
U-1769 |
— | Subutex |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.